Advertisement

Use of Blood Components

  • Firoozeh Alvandi
  • Saleh Ayache
  • Elizabeth T. Drum
  • Jay H. Herman
Chapter

Abstract

After studying this chapter, you should be able to: Describe the composition of the different components extracted from whole blood. Assess the impact of anemia, particularly in critical care patients and patients with cardiovascular disease. Recognize clinical indications, clinical thresholds, and contraindications for the use of specific blood components. Recognize various aspects of platelet refractoriness. Recognize the risk associated with transfusion. Describe the modifications to blood components and recognize the indications for the use of modified blood components. Identify alternatives and adjuncts to allogeneic blood component transfusion.

Keywords

Human Leukocyte Antigen Disseminate Intravascular Coagulation Thrombotic Thrombocytopenic Purpura Blood Component Massive Transfusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Klein HG, Anstee DJ. Mollison’s Blood Transfusion in Clinical Medicine. 11th ed. Oxford: Blackwell; 2005.CrossRefGoogle Scholar
  2. 2.
    Stehling LC, Doherty DC, Faust RJ, et al. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology. 1996;84:732-747.CrossRefGoogle Scholar
  3. 3.
    Ostgaard G. and postoperative normovolemic anemia. Physio­logical compensation, monitoring and risk evaluation. Tidsskr Nor Laegeforen. 1996;116:57-60.PubMedGoogle Scholar
  4. 4.
    Buckberg G, Brazier J. Coronary blood flow and cardiac function during hemodiluation. Bible Haematol. 1974;41:173-189.Google Scholar
  5. 5.
    Majdpour C, Spahn, DR, Weiskopf RB. Anemia and perioperative red blood cell transfusion: a matter of tolerance. Critical Care Med. 2006;34:S102-S108.CrossRefGoogle Scholar
  6. 6.
    Mintz PD, ed. Transfusion Therapy Clinical Principles and Practice. 2nd ed. Bethesda, Md: AABB Press; 2005.Google Scholar
  7. 7.
    Duke M, Abelmann WH. The hemodynamic response to chronic anemia. Circulation. 1969;39:503.PubMedCrossRefGoogle Scholar
  8. 8.
    Ickx BE, Rigolet M, Van Der Linden PJ. Cardiovascular and metabolic response to acute normovolemic anemia: effects of anesthesia. Anesthesiology. 2000;93:1011-1016.PubMedCrossRefGoogle Scholar
  9. 9.
    Concensus Conference. Perioperative red blood cell transfusion. JAMA.1988;260:2700-2703.Google Scholar
  10. 10.
    Carson JL, Hill S, Carless P, et al. Transfusion triggers: a systematic review of the literature. Trans Med Rev. 2002;16:187-199.CrossRefGoogle Scholar
  11. 11.
    Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet. 2007;370:415-426.PubMedCrossRefGoogle Scholar
  12. 12.
    Hébert PC, Wells G, Blajchman MA, et al. A multicenter randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409-417.PubMedCrossRefGoogle Scholar
  13. 13.
    Hébert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular disease? Crit Care Med. 2001;29:227-234.PubMedCrossRefGoogle Scholar
  14. 14.
    Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356:1609-1619.PubMedCrossRefGoogle Scholar
  15. 15.
    Armano R, Gauvin F, Ducruet T, et al. Determinants of red blood cell transfusions in a pediatric critical care unit: A prospective, descriptive epidemiological study. Crit Care Med. 2005;33:2637-2644.PubMedCrossRefGoogle Scholar
  16. 16.
    Spence RK, Carson JA, Poses R, et al. Elective surgery without transfusion: Influence of preoperative hemoglobin level and blood loss on mortality. Am J Surg. 1990;159:320-324.PubMedCrossRefGoogle Scholar
  17. 17.
    Carson JL, Spence RK, Poses RM, et al. Severity of anaemia and operative mortality and morbidity. Lancet. 1988;1(8588):727-729.PubMedCrossRefGoogle Scholar
  18. 18.
    Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996;348:1055-1060.PubMedCrossRefGoogle Scholar
  19. 19.
    Rosse WF, Narla M, Petz LD, Steinberg MH. New views of sickle cell disease pathophysiology and treatment. (American Society of Hematology Education Program Book) Hematology. 2000:2-17.Google Scholar
  20. 20.
    Vichinsky EP, Earler A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Eng J Med. 1990;322:1617-1621.CrossRefGoogle Scholar
  21. 21.
    Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion. 2002;42:684-690.PubMedCrossRefGoogle Scholar
  22. 22.
    Herman JH, Chambers LA. Considerations in the selection of a platelet component: apheresis versus whole blood-derived. Transfus Med Rev. 1999;13:311-322.PubMedCrossRefGoogle Scholar
  23. 23.
    Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601-3606.PubMedGoogle Scholar
  24. 24.
    Gmür J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet. 1991;338(8777):1223-1236.PubMedCrossRefGoogle Scholar
  25. 25.
    Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Oncology. J Clin Oncol. 2001;19:1519-1538.PubMedGoogle Scholar
  26. 26.
    Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusion in adults with acute myeloid leukemia. N Eng J Med. 1997;337:1870-1875.CrossRefGoogle Scholar
  27. 27.
    Pisciotto PT, Benson K, Hume, et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion. 1995;35:498-502.Google Scholar
  28. 28.
    Daly PA, Schiffer CA, Aisner J, Wiernik PH. Platelet transfusion therapy:one-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA. 1980;243:435-438.PubMedCrossRefGoogle Scholar
  29. 29.
    Lee EJ, Schiffer CA. ABO compatibility can influence the results of platlet transfusion. Results of a randomized trial. Transfusion. 1989;29:384-389.Google Scholar
  30. 30.
    Gottschall J, ed. Blood Transfusion Therapy A Physician’s Handbook. 8th ed. Bethesda, MD: AABB Press; 2005:15-22.Google Scholar
  31. 31.
    Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion. 2006;46:1279-1285.PubMedCrossRefGoogle Scholar
  32. 32.
    Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2007;22:106-175.PubMedCrossRefGoogle Scholar
  33. 33.
    McLeod BC. Therapeutic apheresis: Use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange. Best Pract Res Clin Haematol. 2006;19:157-167.PubMedCrossRefGoogle Scholar
  34. 34.
    Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med. 1980;303:1318-1322.PubMedCrossRefGoogle Scholar
  35. 35.
    Nuttall GA, Brost BC, Connis RT, et al. Practice Guidelines for Perioperative Blood Transfusion and Adjuvant Therapies (approved by the House of Delegates on October 22, 1995 and last amended on October 25, 2005) An updated report by the American Society of Anesthesiologist Task Force on Perioperative Blood Transfusion and Adjuvant Therapies.Google Scholar
  36. 36.
    Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med. 2007;131:702-707.PubMedGoogle Scholar
  37. 37.
    Dodd RY, Notari EP IV, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975-979.PubMedCrossRefGoogle Scholar
  38. 38.
    Popovsky MA, ed. Transfusion Reactions. 3rd ed. Bethesda, MD: AABB Press; 2007.Google Scholar
  39. 39.
    Petz LD, Garratty G, editors. Immune Hemolytic Anemias. 2nd ed. Philadelphia: Churchill Livingstone; 2004:547-555.Google Scholar
  40. 40.
    Toy P, Popovsky MA, Abraham E, et al. The National Heart, Lung and Blood Institute Working Group on TRALI. Transfusion-related acute lung injury: definition and review. Crit Care Med. 2005;33:721-726.PubMedCrossRefGoogle Scholar
  41. 41.
    Toy P, Gajic O. Transfusion-related acute lung injury. Anesth Analg. 2004;99:1623-1624.PubMedCrossRefGoogle Scholar
  42. 42.
    McFarland J, Menitove J, Kagen L, et al. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B radiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Eng J Med. 1997;337:1861-1869.Google Scholar
  43. 43.
    Novotany VMJ, Van Dooren R, Witvliet MD, et al. Occurrence of allogeneic HLA and non-HLA antibodies after transfusions of prestorage filtered platelets and red blood cells: a prospective study. Blood. 1995;85:1736-1741.Google Scholar
  44. 44.
    Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86:3598-3603Google Scholar
  45. 45.
    American Red Cross, America’s Blood Centers, American Association of Blood Banks. Circular of information for the use of human blood and blood components. Bethesda, MD: AABB; 2003.Google Scholar
  46. 46.
    Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind, placebo-controlled randomized trial. Lancet. 2003;361:201-205.PubMedCrossRefGoogle Scholar
  47. 47.
    Novel WM. Hemostatic alternatives in reconstructive surgery. Semin Hematol. 2004;41:163-167.CrossRefGoogle Scholar
  48. 48.
    Martinowitz U, Kenet G, Segale N, et al. Recombinant activated factor VII inadjunctive hemorrhage control in trauma. J Trauma. 2001;51:431-439.PubMedCrossRefGoogle Scholar
  49. 49.
    Weiskopf RB. Intraoperative use of recombinant activated coagulation factor VII. Anesthesiology. 2002;96:1287-1289.PubMedCrossRefGoogle Scholar
  50. 50.
    Vlot AJ, Ton E, MacKaay AJ, et al. Treatmnet of serverely bleeding patients without pre-existing coagulopathy with activated recombinant factor VII. Am J Med. 2000;108:421-423.PubMedCrossRefGoogle Scholar
  51. 51.
    Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004;57:709-719.PubMedCrossRefGoogle Scholar
  52. 52.
    Malone DL, Hess JR, Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma. 2006;60:S91-S96.PubMedCrossRefGoogle Scholar

Additional Reading

  1. Gottschall J, ed. Blood Transfusion Therapy a Physician’s Handbook. 8th ed. Bethesda, MD: AABB Press; 2005:15-22.Google Scholar
  2. Mintz PD, ed. Transfusion Therapy Clinical Principles and Practice. 2nd ed. Bethesda, MD: AABB Press; 2005.Google Scholar
  3. Klein HG, Anstee DJ. Mollison’s Blood Transfusion in Clinical Medicine. 11th ed. Oxford: Blackwell; 2005.CrossRefGoogle Scholar
  4. Popovsky MA, ed. Transfusion Reactions. 3rd ed. Bethesda, MD: AABB Press; 2007.Google Scholar
  5. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet. 2007;370:415-426.PubMedCrossRefGoogle Scholar
  6. Hébert PC, Wells G, Blajchman MA, et al. A multicenter randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409-417.PubMedCrossRefGoogle Scholar
  7. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Oncology. J Clin Oncol. 2001;19:1519-1538.PubMedGoogle Scholar
  8. McFarland J, Menitove J, Kagen L, et al. The Trial to reduce alloimmunization to platelets study group. leukocyte reduction and ultraviolet B radiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Eng J Med. 1997;337:1861-1869.Google Scholar
  9. Herman J, Chambers LA. Considerations in the selection of a platelet component: apheresis versus whole blood-derived. Transfus Med Rev. 1999;13:311-322.PubMedCrossRefGoogle Scholar
  10. Stehling LC, Doherty DC, Faust RJ, et al. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on blood component therapy. Anesthesiology. 1996;84:732-747.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Firoozeh Alvandi
    • 1
  • Saleh Ayache
    • 1
  • Elizabeth T. Drum
    • 2
  • Jay H. Herman
    • 3
  1. 1.U.S. Food and Drug AdministrationSilver SpringUSA
  2. 2.Department of AnesthesiologyTemple University School of MedicinePhiladelphiaUSA
  3. 3.Department of Medicine and Pathology, Anatomy and Cell BiologyThomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations